CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
通用型 CAR-T 细胞在肿瘤免疫治疗中的现状与展望
英文原题：Current status and perspective of off-the-shelf CAR-T cells in cancer immunotherapy.
查看英文原题
Current status and perspective of off-the-shelf CAR-T cells in cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫治疗近期进展凸显了现货型嵌合抗原受体（CAR）T细胞疗法的潜力。该疗法可解决传统自体方法的关键局限，如需患者特异性细胞采集和生产周期较长。本综述总结CAR-T 技术的发展、临床应用及挑战，回顾CAR设计和功能、癌症靶向机制，以及可替代患者特异性细胞采集的通用供者平台开发策略。文章讨论CAR-T 技术的主要挑战及潜在解决方法，也概述近期获得FDA批准的CAR-T 细胞疗法。最后，综述探讨未来方向、监管挑战及精准医疗潜力，强调现货型CAR-T 疗法如何通过提高可规模化生产和可及性，改变癌症治疗格局。
展开英文摘要原文
Recent advances in cancer immunotherapy have highlighted the promise of off-the-shelf chimeric antigen receptor (CAR)-T cell therapy. This has offered solutions to key limitations of conventional autologous approaches, such as patient-specific cell collection and lengthy production times. This review summarizes the development, clinical application, and challenges of CAR-T cell technology.
We reviewed CAR design and function, cancer-targeting mechanisms, and approaches to developing universal donor platforms that could replace the need for patient-specific cell harvesting.
We discussed key challenges of CAR-T technology and its potential solutions. This review also summarizes CAR-T cell therapies recently approved by the FDA.
Finally, we explored future directions, regulatory challenges and the potential of personalized medicine, emphasizing how off-the-shelf CAR-T therapies could revolutionize cancer treatment by making it more scalable and accessible.
论文信息
- 作者
- Fallahianshafiei S、Babaeizad A、Yang P、La'ah AS、Sheykhhasan M
- 第一作者单位
- Department of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.Iran
- 通讯作者单位
- Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran. Electronic address: msheykhhasan@muq.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026 Feb
- 原文标识
- PubMed 41512559 · DOI 10.1016/j.biopha.2026.118986